In the journal Neurology, was published three articles informing about the rare potential side effects of alemtuzumab (alemtuzumab) in patients with relapsing multiple sclerosis remissionem (RRRS).
As reported by Medpage Today, it was about eight akumulatora cases of acute cholecystitis (OAHU), two cases of hemophagocytic lymphohistiocytosis (HLH) and one case of coronary heart disease (CHD).
Alemtuzumab, a humanized monoclonal antibody against the CD52 antigen of lymphocytes, is introduced intravenously and normally applied as a third line therapy RRRS. Syndrome release of cytokines is the most common side effect alemtuzumab associated with the infusion.
Described in detail in the Neurology cases of adverse reactions emphasize the problem of correlation between high efficiency and potentially lethal complications of therapy of multiple sclerosis, the authors of the work. In their view, vigilant post-marketing surveillance of new drugs play an important role.
“Anyone who discovers a rare or delayed adverse events associated with the use of drugs, it is recommended to publish your experience. Understanding the risks will be of critical importance for physicians and patients to make informed decisions regarding treatment with new drugs,” the researchers concluded.